3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
4
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Glioma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uveal Melanoma
1
Thrombocytosis
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Noonan Syndrome 6
1
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoproliferative Disorders
×
entrectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled